Drug news
EU approves Tasigna for newly diagnosed Ph+CML
European Commission approved Tasigna (nilotinib) from Novartis for the treatment of patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML) in chronic phase.A decision based on the results of the ENESTnd trial demonstrating superiority to the standard of care Glivec (imatinib) in achieving major molecular response (MMR) and complete cytogenetic response (CCyR) and delaying cancer progression.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.